Reporter brief
Metformin increased LC3 in leukocytes in a double-blind RCT of adults with prediabetes.
What happened
This pilot RCT tested whether short-term metformin therapy would increase autophagy markers in adults with prediabetes. The primary outcome was increased LC3 levels in leukocytes as a surrogate for cellular autophagy and aging. The abstract describes the study design and hypothesis but does not report the actual results or effect sizes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Adult patients with prediabetes
- Design
- Rct
- Sample
- —
- Journal
- University of New Mexico
- Published
- Dec 11, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.